Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the pharma industry. This time, you get to discover 5 hand-picked pharma startups tackling lymphoma.
Global Startup Heat Map highlights 5 Top Pharma Startups tackling Lymphoma out of 139
The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2.093.000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies & relevant startups within a specific field in just a few clicks.
The Global Startup Heat Map below reveals the distribution of the 139 exemplary startups & scaleups we analyzed for this research. Further, it highlights 5 pharma startups that we hand-picked based on criteria such as founding year, location, funding raised, and more. You get to explore the solutions of these 5 startups & scaleups in this report. For insights on the other 134 solutions tackling lymphoma, get in touch.
Carisma Therapeutics develops Macrophage Immunotherapy
While immunotherapy shows some promise, many cancers evade the immune response. The heterogeneity within different cancer cells also raises the chances of the development of resistance against therapeutic antigens. This is why pharma startups are developing chimeric antigenic receptors (CARs). Novel cancer therapies combine CARs with immune cells such as T cells (CAR-T) or macrophages (CAR-M).
Carisma Therapeutics is a US-based startup that develops CAR-M immunotherapy solutions. The startup’s proprietary macrophage platform enables the modulation of the tumor microenvironment for the effective treatment of solid tumors. The macrophages upregulate genes that help in activating and recruiting immune cells.
Catapult Therapeutics offers Humanized Monoclonal Antibodies
Monoclonal antibodies find applications in cancer immunotherapy where they specifically target particular antigens on tumor cells. However, therapeutic antibodies generally have high immunogenicity, often leading to adverse effects. Humanized antibodies avoid such effects as well as allow precise regulations of effector functions. Pharma startups are developing humanized antibodies to treat lymphoma among other cancers.
Dutch startup Catapult Therapeutics provides humanized monoclonal antibodies. CAP-100, the startup’s lead candidate, is a humanized monoclonal antibody that targets CCR7, a receptor overexpressed in many hematological malignancies, including lymphoma. In preclinical studies, it inhibits the migration and survival of primary tumor cells in patients with non-Hodgkin lymphoma. Having undergone preclinical development, CAP-100 finds promise both as monotherapy and in combination with other therapies.
Stimunity provides Biopharmaceuticals
Chemotherapy is particularly useful for the treatment of both Hodgin and non-Hodgkin lymphoma. However, it causes many short-term side effects such as hair loss, diarrhea, fatigue, and nausea. More worryingly, some chemo drugs might cause long-lasting side effects such as damage to the heart and lungs. This is why pharma startups are working on biopharmaceuticals that specifically target pathways overexpressed in cancers, including lymphoma.
French startup Stimunity develops biopharmaceuticals to treat patients that don’t respond to immunotherapy. The startup’s immuno-modulator platform targets the stimulator of the interferon genes (STING) pathway. It uses virus-like particles (VLPs) to develop drugs that induce an immune response against tumors or pathogens. It activates dendritic cells and induces a cytotoxic response against cancer cells.
NovalGen produces Bispecific Antibody Therapies
Targeting multiple antigens on a tumor cell increases the specificity of a therapeutic. This is why interest in bispecific antibody therapies is rising in the pharma industry. Such antibody therapies improve the efficiency of retargeting immune cells to tumors and blocking tumor signaling molecules. Pharma startups are engineering bispecific antibodies for use as therapeutics for the treatment of lymphomas and other cancers.
NovalGen is a British startup producing bispecific antibody therapies. The startup’s integrated protein engineering platform adds novel attributes to bispecific antibodies. NovalGen’s lead drug candidate, NVG-111, is a first-in-class bispecific antibody for hematological and solid tumors. It targets the receptor tyrosine kinase-like orphan receptor 1 (ROR1) in mantle cell lymphoma (MCL) and lymphocytic leukemia. The drug acts by engaging T cells that kill cancer stem cells (CSCs), reducing the risk of tumor recurrence.
Bioceltix develops Canine Lymphoma Drug
Lymphoma constitutes one of the most common types of cancers in dogs. Limitations of current diagnostic solutions mean that most cases are detected in advanced stages. Moreover, dogs exhibit high systemic toxicity in response to cytostatic drugs, further reducing the efficacy of any chemotherapy. This is why pharma startups are working on more effective drugs for late-stage canine lymphoma.
Polish startup Bioceltix develops stem cell therapies for veterinary use. The startup is working on a drug that combines a monoclonal antibody and a cytostatic moiety. The drug leverages the immunomodulatory properties of mesenchymal stem cells (MSCs). It precisely targets cancer stem cells (CSCs) only, thereby increasing the treatment efficacy and minimizing toxic effects.
Discover more Pharma Startups
Pharma startups such as the examples highlighted in this report focus on ovarian cancer, stomach cancer, lung cancer as well as cancer vaccines. While all of these technologies play a major role in advancing the pharma industry, they only represent the tip of the iceberg. To explore more pharma technologies, simply get in touch to let us look into your areas of interest. For a more general overview, you can download our free Pharma Innovation Report to save your time and improve strategic decision-making.